Ewing Sarcoma as Secondary Malignant Neoplasm-Epidemiological and Clinical Analysis of an International Trial Registry.
Ewing sarcoma
cancer survivor
childhood cancer
secondary malignancy
secondary malignant neoplasms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2022
30 Nov 2022
Historique:
received:
29
09
2022
revised:
17
11
2022
accepted:
28
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Ewing sarcoma (EwS) is the second most common bone and soft tissue tumor, affecting primarily adolescents and young adults. Patients with secondary EwS are excluded from risk stratification in several studies and therefore do not benefit from new therapies. More knowledge about patients with EwS as secondary malignant neoplasms (SMN) is needed to identify at-risk patients and adapt follow-up strategies. Epidemiology, clinical characteristics, and survival analyses of EwS as SMN were analyzed in 3844 patients treated in the last three consecutive international EwS trials, EICESS 92, Euro-E.W.I.N.G. 99, and EWING 2008. Forty-two cases of EwS as SMN (approximately 1.1% of all patients) were reported, preceded by a heterogeneous group of malignancies, mainly acute lymphoblastic leukemias (
Identifiants
pubmed: 36497417
pii: cancers14235935
doi: 10.3390/cancers14235935
pmc: PMC9735743
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Krebshilfe
ID : DKH M43/92/Jü2, 108128, 70-2551 Jü3 and DKH 70112018
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Clin Oncol. 2010 Jul 10;28(20):3284-91
pubmed: 20547982
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
J Oncol. 2010;2010:397632
pubmed: 20300555
Sarcoma. 2011;2011:736841
pubmed: 20981341
Int J Cancer. 2014 Oct 15;135(8):1764-73
pubmed: 24945137
Pediatr Blood Cancer. 2014 Oct;61(10):1877-9
pubmed: 24753445
J Clin Oncol. 2000 Sep;18(17):3108-14
pubmed: 10963639
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
J Clin Med. 2021 Apr 14;10(8):
pubmed: 33919988
Blood. 2008 Jun 15;111(12):5515-23
pubmed: 18334672
Sarcoma. 2016;2016:5043640
pubmed: 27524931
Jpn J Clin Oncol. 2013 Apr;43(4):417-21
pubmed: 23475435
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
N Engl J Med. 1991 Nov 7;325(19):1330-6
pubmed: 1922234
Cancer. 2011 Jul 1;117(13):3027-32
pubmed: 21692057
Oncogene. 1993 Sep;8(9):2449-56
pubmed: 8361758
Nat Genet. 2015 Sep;47(9):1073-8
pubmed: 26214589
Nature. 1992 Sep 10;359(6391):162-5
pubmed: 1522903
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-12
pubmed: 32213089
Int J Mol Sci. 2015 Jul 16;16(7):16176-215
pubmed: 26193259
Nat Rev Dis Primers. 2018 Jul 5;4(1):5
pubmed: 29977059
Pediatr Blood Cancer. 2013 Apr;60(4):611-5
pubmed: 22847990
Hematol Oncol Clin North Am. 1993 Apr;7(2):401-15
pubmed: 8468273
Klin Padiatr. 2015 Nov;227(6-7):329-34
pubmed: 26457956
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):224-30
pubmed: 22795729
J Clin Oncol. 2007 Mar 1;25(7):793-8
pubmed: 17283364
Clin Pharmacokinet. 1991 Mar;20(3):194-208
pubmed: 2025981
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
Semin Radiat Oncol. 2010 Jan;20(1):67-78
pubmed: 19959033
Cancer. 2008 May 1;112(9):2071-9
pubmed: 18327823
J Natl Cancer Inst. 2007 Feb 21;99(4):300-8
pubmed: 17312307
J Clin Oncol. 2011 Aug 1;29(22):3056-64
pubmed: 21709189
Nat Rev Cancer. 2002 Feb;2(2):124-32
pubmed: 12635175
Cancer Epidemiol. 2020 Oct;68:101779
pubmed: 32682319
Cancer. 2006 Jul 1;107(1):201-6
pubmed: 16721801
Pediatr Clin North Am. 2015 Feb;62(1):61-73
pubmed: 25435112
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734